Prevention of Rejection When 14C3 Cells Recognize Recipient Alloantigens
| Marrow Donor . | Recipient . | T Cells Added . | Recipients Tested . | Recipients Engrafted . | Percent Engrafted . |
|---|---|---|---|---|---|
| B6C3 | CB6 | None | 14 | 0 | 0 |
| LN T | 15 | 15 | 100 | ||
| 14C3 | 15 | 13 | 87 | ||
| B6SJL | CB6 | None | 10 | 1 | 10 |
| LN T | 8 | 8 | 100 | ||
| 14C3 | 10 | 9 | 90 | ||
| B6.Ly5a | bm1 | None | 14 | 2 | 14 |
| LN T | 11 | 9 | 82 | ||
| 14C3 | 15 | 3 | 20 |
| Marrow Donor . | Recipient . | T Cells Added . | Recipients Tested . | Recipients Engrafted . | Percent Engrafted . |
|---|---|---|---|---|---|
| B6C3 | CB6 | None | 14 | 0 | 0 |
| LN T | 15 | 15 | 100 | ||
| 14C3 | 15 | 13 | 87 | ||
| B6SJL | CB6 | None | 10 | 1 | 10 |
| LN T | 8 | 8 | 100 | ||
| 14C3 | 10 | 9 | 90 | ||
| B6.Ly5a | bm1 | None | 14 | 2 | 14 |
| LN T | 11 | 9 | 82 | ||
| 14C3 | 15 | 3 | 20 |
Groups of the five irradiated CB6 (800 cGy) or bm1 (550 cGy) recipients were transplanted with 5.0 × 106 T cell-depleted B6C3, B6SJL, or B6.Ly5a marrow cells alone (negative controls), with LN T cells (2.5 × 105 from B6C3 donors, 1.0 × 106 from B6SJL donors, and 2.5 × 105 from B6.Ly5a donors) added (positive controls), or with 20 × 106 14C3 cells added. All recipients were treated with IL-2 (2,000 U intraperitoneally) on the day of transplant and for 6 consecutive days thereafter. Engrafted recipients tested at 2 months after transplantation (n = 42) had 24% to 100% (mean, 91.5%) donor-derived granulocytes in the blood. Engrafted recipients last tested at 1 month after transplantation (n = 18) had 64% to 100% (mean, 96.3%) donor-derived granulocytes in the blood. Recipients with rejection had 1% to 13% (mean, 4.3%) donor-derived granulocytes when last tested at 1 to 2 months after transplantation. The table shows results pooled from three separate experiments.